Repository logo
 
Publication

Sumac fruit supplementation improve glycemic parameters in patients with metabolic syndrome and related disorders: a systematic review and meta-analysis

2021Journal article Restricted access
Simple item page
dc.contributor.authorGhafouri, Atie
dc.contributor.authorEstêvão, M. Dulce
dc.contributor.authorAlibakhshi, Pooya
dc.contributor.authorPizarro, Ana Beatriz
dc.contributor.authorKashani, Amirhossein Faghihi
dc.contributor.authorPersad, Emma
dc.contributor.authorHeydari, Hafez
dc.contributor.authorHasani, Motahareh
dc.contributor.authorHeshmati, Javad
dc.contributor.authorMorvaridzadeh, Mojgan
dc.date.accessioned2021-10-07T18:33:50Z
dc.date.available2021-10-07T18:33:50Z
dc.date.issued2021
dc.description.abstractBackground: Metabolic syndrome (MetS) is the one of the main causes of mortality worldwide. Several randomized controlled trials (RCTs) have revealed the beneficial effects of sumac (Rhus coriaria) on cardiometabolic risk factors. However, the entirety of the evidence has yet to be summarized in a systematic review. Objective: The aim of this systematic review and meta-analysis was to evaluate the effects of sumac on several cardiometabolic risk factors in patients with MetS and related disorders. Methods: We reviewed Medline, Scopus, Web of Science and Cochrane CENTRAL for RCTs published from inception to December 2020 evaluating the impact of sumac in adults with MetS or related disorders. Outcome measures included anthropometric measures, glycemic indices, blood lipids, blood pressure and liver enzymes. Pooled effect sizes were reported as standard mean differences (SMDs) and 95% confidence intervals (CIs). Trials were pooled using a random effects model. Results: Nine studies enrolling 526 participants met the inclusion criteria for this meta-analysis. Our results indicate that sumac intake significantly decrease fasting blood sugar (FBS) (SMD: 0.28; 95% CI: 0.54, -0.02; I-2 = 00.0%), insulin (SMD: 0.67; 95% CI: 0.99, -0.36; I-2 = 03.7%), and insulin resistance (measured through the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)) (SMD: 0.79; 95% CI: 1.24, -0.34; I-2 = 50.1%). Sumac intake did not have a significant impact on weight, body mass index (BMI), waist circumference (WC), hip circumference (HC), waist to hip ratio (WHR), HbA1c, total cholesterol (TC), triglycerides (TG), high density lipoproteins (HDL), low density lipoprotein (LDL), systolic blood pressure (SBP), diastolic blood pressure (DBP), aspartate transaminase (AST) and alanine transaminase (ALT). Conclusion: Sumac, as an adjuvant therapy, may decrease serum levels of FBS, insulin and HOMA-IR. However, due to high heterogeneity in the included studies, these findings must be interpreted with great caution. Larger, well-designed placebo-controlled clinical trials are still needed to further evaluate the capacity of sumac as a complementary treatment to control MetS risk factors.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.doi10.1016/j.phymed.2021.153661pt_PT
dc.identifier.issn0944-7113
dc.identifier.urihttp://hdl.handle.net/10400.1/17201
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherElsevierpt_PT
dc.subjectSumacpt_PT
dc.subjectRhus coriariapt_PT
dc.subjectMetabolic syndromept_PT
dc.subjectGlycemic controlpt_PT
dc.titleSumac fruit supplementation improve glycemic parameters in patients with metabolic syndrome and related disorders: a systematic review and meta-analysispt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.startPage153661pt_PT
oaire.citation.titlePhytomedicinept_PT
oaire.citation.volume90pt_PT
person.familyNameEstêvão
person.givenNameMaria Dulce da Mota Antunes de Oliveira
person.identifierI-4695-2014
person.identifier.ciencia-id881B-53E8-0DB1
person.identifier.orcid0000-0002-7151-8363
person.identifier.scopus-author-id8381590400
rcaap.rightsrestrictedAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication67887883-2695-48cc-8221-aa46780ac143
relation.isAuthorOfPublication.latestForDiscovery67887883-2695-48cc-8221-aa46780ac143

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
10.1016j.phymed.2021.153661.pdf
Size:
3.57 MB
Format:
Adobe Portable Document Format
Download

Collections

ESS2-Artigos (em revistas ou actas indexadas)